SenseTime secures hundreds of millions in Pre-A+ funding to advance intelligent healthcare transformation

On November 17, SenseTime Medical has recently secured hundreds of millions of yuan in a Pre-A+ strategic funding round. Investors in this round included Lenovo Capital, NewMargin Ventures, Chord Capital, and Shenran Investment. Earlier this year, the company had already received over one hundred million yuan in funding from strategic investors.

According to SenseTime Medical, the company has kicked off its Series A funding round at a post-money valuation of over RMB 3 billion. The round has already been oversubscribed, with commitment amounts exceeding RMB 500 million.

SenseTime Medical is advancing its "Hospital of the Future" initiative through an AI-driven strategy termed "General-Specialist Integration." The core technological engines underpinning this vision include its medical large language model "Dayi" and a suite of multi-modal foundational models for medical imaging.

The "Dayi" is built upon SenseTime's "SenseChat" large language model—a foundation model with hundreds of billions of parameters—and has been trained using massive volumes of high-quality medical knowledge data. It exhibits capabilities in perception, reasoning, and planning. Currently, the model supports multiple specialized healthcare scenarios, including intelligent self-diagnosis, medication consultation, structured imaging reporting, and clinical decision support.

Multimodal Medical Imaging Foundation Model Groups, integrating data modalities such as medical images, text, and bioinformatics, are designed to support tasks—including detection, segmentation, and classification—across various imaging types such as radiology and pathology. These models facilitate highly efficient training with limited samples and weak supervision, aiming to overcome the "long-tail problem" in healthcare, where data scarcity and high annotation costs remain major bottlenecks.

According to Dr. Zhang Shaoting, CEO of SenseTime Medical, "In the increasingly competitive medical AI sector, pure technological innovation can provide an early-mover advantage but seldom sustains as a long-term barrier. In contrast, a diverse product portfolio and a capital-enabled industrial ecosystem—empowered by underlying technology—are far less replicable."

As early as 2018, SenseTime Medical introduced the platform concept of "Empowering Full-Hospital Diagnosis, Treatment, and Recovery." This vision has since evolved to include practical applications in clinical diagnosis and treatment, intelligent decision-making, patient services, and medical research—covering the entire patient journey and care continuum.

This platform-based strategy also aligns with the implicit needs of hospitals. Many medical institutions prefer suppliers that offer scalable products, rather than having to install dozens of different software applications from numerous vendors. An example of this is Kiang Wu Hospital in Macau, which has successively adopted over ten AI solutions from SenseTime Medical over the years.

To avoid being trapped in the price competition of standardized software products, SenseTime Medical has established a dual-middle-platform system for agent development and model application production. This creates a differentiated advantage characterized as "autonomy and controllability + flexible allocation." Hospitals can not only leverage the underlying large-scale model capabilities but also, by utilizing the dual middle platforms, develop specialized models and agents tailored to specific domains based on their own strengths. This enables them to achieve a comprehensive upgrade toward smart hospital operations.

According to reports, after SenseTime Group implemented its "1+X" strategy, SenseTime Medical began operating independently in the market, with its commercialization path becoming increasingly clear. On one hand, it continues to focus on large-scale "hospital-wide intelligence" projects; on the other hand, it extends standardized software modules to grassroots hospitals to expand revenue scale.

"With nearly seven to eight years of experience in healthcare, SenseTime Medical's early investments have resulted in a diverse product portfolio. The move to seek independent financing is also driven by the intention to bring in strategic shareholders with valuable resources—it's not just about raising capital, but also about building a collaborative ecosystem."

Zhang Shaoting noted that, going forward, SenseTime Medical will continue to introduce industrial partners and financial investors with ecosystem synergies to jointly build an AI healthcare ecosystem and accelerate the intelligent transformation of the medical industry.